Loading, Please Wait...
SEATTLE, March 07, 2019 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today reported financial results for the fourth quarter and year ended December 31, 2018.
Fourth Quarter Financial Highlights
Full Year 2018 Financial Highlights
“Our record product and service revenue in 2018 was driven by a growing nCounter installed base and strong consumable pull-through and we believe we can deliver double-digit revenue growth in our core nCounter business in 2019,” said Brad Gray, president and CEO of NanoString. “Interest in our GeoMx Digital Spatial Profiler has consistently exceeded our expectations and we expect to accelerate our top-line growth in the second half of 2019 following the commercial launch of GeoMx.”
Recent Business Highlights
nCounter Platform
GeoMx DSP Platform
Hyb & Seq Platform
Finance
Fourth Quarter Financial Results
Product and service revenue for the three months ended December 31, 2018 increased by 12% to $23.6 million compared to $21.0 million for the three months ended December 31, 2017. Instrument revenue was $5.9 million, a reduction of 1% compared to the prior year period. Consumables revenue, excluding Prosigna, was $13.1 million, an increase of 14% compared to the prior year period, with growth driven primarily by sales of our panel products. Prosigna IVD kit revenue was $2.2 million, an increase of 24% compared to the prior year period, as more testing laboratories commenced providing services and testing volumes increased, most significantly in territories outside of the United States. Service revenue was $2.5 million, an increase of 36% compared to the prior year period, reflecting increased service contracts associated with our growing installed base of nCounter instruments, as well as demand for our GeoMx DSP Technology Access Program. Gross margin on product and service revenue was 54% compared to 56% in the prior year period, reflecting a greater mix of SPRINT as a percentage of instrument sales in the current quarter.
Collaboration revenue totaled $6.4 million, compared to $14.2 million for the prior year period, and was derived primarily from our collaborations with Lam Research and Celgene Corporation. The prior year period included, in addition to revenue derived from our Lam and Celgene collaborations, the accelerated recognition of $11.6 million of deferred revenue related to our Merck collaboration as a result of Merck electing not to pursue a PMA filing for the companion diagnostic under development. Cash received from collaborators totaled $3.8 million, primarily reflecting expected activity relating to our collaboration with Lam Research.
Research and development expense increased by 21% to $16.5 million compared to $13.7 million for the prior year period, reflecting investments in new products and technologies under development, including our GeoMx DSP and Hyb & Seq technologies. Selling, general and administrative expense increased by 3% to $20.3 million compared to $19.7 million for the prior year period, primarily reflecting higher accounting and professional fees relating to our compliance with the Sarbanes Oxley Act.
Net loss was $21.1 million, or a loss of $0.68 per share, compared with $8.8 million, or $0.34 per share for the prior year period, reflecting primarily the differences in collaboration revenue recognized and the increased investments in research and development in the current quarter.
Full Year 2018 Financial Results
Product and service revenue for 2018 increased by 16.0% to $83.5 million compared to $72.0 million for 2017. Instrument revenue was $21.4 million, an increase of 3% compared to the prior year. Consumables revenue, excluding Prosigna, was $43.8 million for 2018, an increase of 14% compared to the prior year. Prosigna IVD kit revenue was $9.4 million, an increase of 40% compared to the prior year. Service revenue was $8.8 million, an increase of 44% compared to the prior year. Collaboration revenue totaled $23.2 million and cash received from collaborators was $23.6 million, compared to $42.9 million and $22.7 million, respectively, for the prior year. Gross margin on product and service revenue was 57% compared to 56% in 2017.
Research and development expense increased by 31% to $61.6 million as compared to $46.9 million for the prior year. Selling, general and administrative expense increased by 5% to $78.2 million compared to $74.3 million for the prior year.
Net loss for 2018 was $77.4 million, or $2.78 per share compared with $43.6 million, or a loss of $1.84 per share for the prior year.
The company ended 2018 with approximately $94.0 million of cash, cash equivalents, and short-term investments.
Outlook for 2019
The company, based on its plans and initiatives for 2019, expects to record results approximately as presented below.
Conference Call
Management will host a conference call today beginning at 1:30 pm PT / 4:30 pm ET to discuss these results and answer questions. Individuals interested in listening to the conference call may do so by dialing (888) 793-9492 for domestic callers, or (734) 385-2643 for international callers. Please reference Conference ID 4080336. To listen to a live webcast, please visit the investor relations section of the company’s website at www.nanostring.com. A replay of the call will be available beginning March 7, 2019 at 7:30pm ET through midnight ET on March 14, 2019. To access the replay, dial (855) 859-2056 or (404) 537-3406 and reference Conference ID: 4080336. The webcast will also be available on the company’s website for one year following the completion of the call.
About NanoString Technologies, Inc.
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 2,300 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with biopharmaceutical companies to develop companion diagnostics that may be used to identify which patients are most likely to respond to a particular therapeutic treatment. For more information, please visit www.nanostring.com. For more information, please visit www.nanostring.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding expectations for future revenue growth, the impact of new products and expansion into new markets, the company’s anticipated uses of amounts borrowed under its credit facilities, the growth trajectory of the company’s nCounter franchise, the anticipated launch of new platforms, the anticipated increases to the company’s liquidity, the anticipated benefits of the company’s collaboration relationships, the timing of development funding and the company’s estimated 2019 operating results. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include market acceptance of our products; delays or denials of regulatory approvals or clearances for products or applications; delays or denials of reimbursement for diagnostic products; the impact of competition; the impact of expanded sales, marketing, product development and clinical activities on operating expenses; delays or other unforeseen problems with respect to manufacturing, product development or clinical studies; adverse conditions in the general domestic and global economic markets; as well as the other risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. NanoString Technologies disclaims any obligation to update these forward-looking statements.
The NanoString logo, NanoString, NanoString Technologies, GeoMx, Hyb & Seq, SPRINT, nCounter and Prosigna are registered trademarks or trademarks of NanoString Technologies, Inc. in various jurisdictions.
Contact
Doug Farrell
Vice President, Investor Relations & Corporate Communications
dfarrell@nanostring.com
Phone: 206-602-1768
NANOSTRING TECHNOLOGIES, INC. | |||||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||||||
(In thousands, except per share amounts) | |||||||||||||||
(Unaudited) | |||||||||||||||
Three Months Ended December 31, |
Years Ended
December 31, |
||||||||||||||
2018 | 2017 | 2018 | 2017 | ||||||||||||
Revenue: | |||||||||||||||
Instruments | $ | 5,850 | $ | 5,890 | $ | 21,441 | $ | 20,839 | |||||||
Consumables | 13,069 | 11,505 | 43,847 | 38,311 | |||||||||||
In vitro diagnostic kits | 2,211 | 1,782 | 9,445 | 6,745 | |||||||||||
Services | 2,511 | 1,843 | 8,790 | 6,115 | |||||||||||
Total product and service revenue | 23,641 | 21,020 | 83,523 | 72,010 | |||||||||||
Collaboration | 6,391 | 14,214 | 23,209 | 42,895 | |||||||||||
Total revenue | 30,032 | 35,234 | 106,732 | 114,905 | |||||||||||
Costs and expenses: | |||||||||||||||
Cost of product and service revenue | 10,793 | 9,188 | 36,331 | 31,880 | |||||||||||
Research and development | 16,531 | 13,675 | 61,599 | 46,888 | |||||||||||
Selling, general and administrative | 20,299 | 19,745 | 78,195 | 74,334 | |||||||||||
Total costs and expenses (a) (b) | 47,623 | 42,608 | 176,125 | 153,102 | |||||||||||
Loss from operations | (17,591 | ) | (7,374 | ) | (69,393 | ) | (38,197 | ) | |||||||
Other income (expense): | |||||||||||||||
Interest income | 505 | 260 | 1,331 | 809 | |||||||||||
Interest expense | (2,633 | ) | (1,568 | ) | (7,431 | ) | (6,153 | ) | |||||||
Other income (expense) | (1,328 | ) | (2 | ) | (1,658 | ) | 183 | ||||||||
Total other income (expense), net | (3,456 | ) | (1,310 | ) | (7,758 | ) | (5,161 | ) | |||||||
Net loss before provision for income taxes | (21,047 | ) | (8,684 | ) | (77,151 | ) | (43,358 | ) | |||||||
Provision for income taxes | (64 | ) | (67 | ) | (249 | ) | (204 | ) | |||||||
Net loss | $ | (21,111 | ) | $ | (8,751 | ) | $ | (77,400 | ) | $ | (43,562 | ) | |||
Net loss per share, basic and diluted | $ | (0.68 | ) | $ | (0.34 | ) | $ | (2.78 | ) | $ | (1.84 | ) | |||
Shares used in calculating basic and diluted net loss per share | 30,853 | 25,392 | 27,883 | 23,731 | |||||||||||
(a) Includes $2.8 million and $3.2 million of stock-based compensation expense for the three months ended December 31, 2018 and 2017, respectively, and $11.5 million and $11.4 million for the years ended December 31, 2018 and 2017, respectively. | |||||||||||||||
(b) Includes $1.1 million and $0.9 million of depreciation and amortization expense for the three months ended December 31, 2018 and 2017, respectively, and $4.1 million and $3.4 million for the years ended December 31, 2018 and 2017, respectively. |
NANOSTRING TECHNOLOGIES, INC. | |||||||
CONDENSED CONSOLIDATED BALANCE SHEETS | |||||||
(In thousands) | |||||||
(Unaudited) | |||||||
December 31, | |||||||
2018 | 2017 | ||||||
Assets | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 24,356 | $ | 26,136 | |||
Short-term investments | 69,641 | 51,419 | |||||
Accounts receivable, net | 17,279 | 19,564 | |||||
Inventory | 13,173 | 20,057 | |||||
Prepaid expenses and other | 7,258 | 4,745 | |||||
Total current assets | 131,707 | 121,921 | |||||
Property and equipment, net | 15,171 | 14,057 | |||||
Other assets | 680 | 784 | |||||
Total assets | $ | 147,558 | $ | 136,762 | |||
Liabilities and Stockholders’ Equity | |||||||
Current liabilities: | |||||||
Accounts payable | $ | 8,636 | $ | 4,092 | |||
Accrued liabilities | 3,705 | 4,507 | |||||
Accrued compensation and other employee benefits | 12,060 | 8,634 | |||||
Customer deposits | 8,167 | 8,945 | |||||
Deferred revenue, current portion | 9,890 | 9,229 | |||||
Deferred rent, current portion | 657 | 512 | |||||
Total current liabilities | 43,115 | 35,919 | |||||
Deferred revenue, net of current portion | 1,620 | 3,304 | |||||
Deferred rent and other liabilities, net of current portion | 7,558 | 8,499 | |||||
Long-term debt, net of discounts | 58,396 | 48,931 | |||||
Total liabilities | 110,689 | 96,653 | |||||
Total stockholders’ equity | 36,869 | 40,109 | |||||
Total liabilities and stockholders’ equity | $ | 147,558 | $ | 136,762 |